Eli Lilly (LLY) Liabilities and Shareholders Equity (2009 - 2026)

Eli Lilly (LLY) has reported Liabilities and Shareholders Equity for 18 consecutive years, with $116.6 billion the latest figure, recorded in Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $116.6 billion, up 30.41% year-over-year; the trailing twelve-month figure through Mar 2026 was $444.9 billion (up 40.98% YoY), and the FY2025 annual result was $112.5 billion, up 42.89% from the prior year.
• Liabilities and Shareholders Equity was $116.6 billion for Q1 2026 at Eli Lilly, up from $112.5 billion in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $116.6 billion in Q1 2026 and troughed at $46.9 billion in Q1 2022.
• Average Liabilities and Shareholders Equity over 5 years is $73.3 billion, with a median of $64.0 billion recorded in 2023.
• Year-over-year, Liabilities and Shareholders Equity dropped 1.56% in 2022 and soared 52.02% in 2025.
• Over 5 years, Liabilities and Shareholders Equity stood at $49.5 billion in 2022, then gained by 29.33% to $64.0 billion in 2023, then gained by 22.98% to $78.7 billion in 2024, then jumped by 42.89% to $112.5 billion in 2025, then rose by 3.65% to $116.6 billion in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $116.6 billion in Q1 2026, $112.5 billion in Q4 2025, and $114.9 billion in Q3 2025.